Prefoldin subunits (PFDN1–6) serve as poor prognostic markers in gastric cancer

Abstract

Prefoldin subunits (PFDN), primarily known for co-chaperone function associated with cytoskeletal rearrangement, have been found involved in epithelial–mesenchymal transition (EMT) and cancer progression. However, studies focusing on the roles of PFDN in gastric cancer (GC) remain limited. The present study aims to evaluate the prognostic values of PFDN in GC. Prognostic roles of PFDNs were analyzed via the Kaplan–Meier platform, followed by subset analysis within various clinical parameters. High mRNA expression of PFDN2, PFDN3 and PFDN4 displayed poor overall survival (OS) while PFDN5 displayed favorable OS. In HER2+ subset, PFDN2, PFDN3, PFDN4 and PFDN6 displayed poor OS. In human epidermal growth factor receptor 2 (HER2−) subset, PFDN2, PFDN3 and PFDN4 displayed poor OS. In intestinal type subset, PFDN1 and PFDN2 displayed poor OS. In diffuse-type subset, PFDN2 and PFDN6 displayed poor OS. In moderate differentiation type subset, PFDN1 displayed poor OS. In poor differentiation type subset, PFDN2 and PFDN6 displayed poor OS. In metastasis negative subset, PFDN1, PFDN2 and PFDN6 displayed poor OS. In lymph node (LN) positive subset, PFDN2 and PFDN5 displayed poor OS. The present study provided insightful clues into the poor prognostic values of PFDNs in GC patients.

Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer

“…Unfortunately, GC is difficult to diagnose at an early stage. Therefore, people are very interested in finding prognostic markers for these potentially curable patients [9][10][11][12][13].…”

The functions and mechanisms of prefoldin complex and prefoldin-subunits

“…The study found that the prefoldin subunit can be used as a strong indicator of poor prognosis of gastric cancer (GC), and the results of subgroup analysis in various clinical parameters show that different prefoldin subunits display different effects the overall survival situation (Table 1) [35].…”

“…In other disease, there is no lack of research on PFDN1. Through the reference gene selection system for nasopharyngeal carcinoma gene expression Gastric cancer [35] Lung cancer [36] Colon cancer [37] Nasopharyngeal carcinoma [38] Mouse Lymphocyte development [27] Cytoskeletal defect [27] PFDN2 Oncogene Human γ-Synuclein [42] Gastric cancer [35] Breast cancer [40] Metastatic urothelial carcinoma [41] Plant [65] PFDN4 Oncogene Human Atherosclerosis [19] Gastric cancer [35,52] Breast cancer [48,49] Colon cancer [51] Hepatocellular carcinoma [50] Atopic dermatitis [53] PFDN6 Human Gastric cancer [35] Acute lymphocytic leukemia [64] Arabidopsis thaliana [76] DELLA [67] Caenorhabditis elegans FOXO [77] α PFDN3/VBP1 Anti-oncogene Human VHL [43] pVHL [44] hMSH4 [45] HDAC1 [46] Gastric cancer [35] Arabidopsis thaliana DELLA [67] Caenorhabditis elegans [66] PFDN5/MM1 Anti-oncogene Human c-Myc [99] TIF1β [101] Rabring7 [127] Egr-1 [128] ARFP/F [129] p73α [133] p63α [134] ΔNp63α [135] Gastric cancer [35] Secondary hyperparathyroidism [54,...…”

<p>The Role of Prefoldin and Its Subunits in Tumors and Their Application Prospects in Nanomedicine</p>

“…The expression of PFDN2 in various subtypes of gastric cancer shows poor overall survival and is a biological indicator of poor prognosis. 26 In type 2 diabetes, anti-PFDN2 antibodies may be useful biomarkers for the disease. 27 PFDN2 has also undergone genetic changes in breast cancer.…”

“…This abnormal expression can also be used as a biomarker to indicate the prognosis of the disease, which is of great significance in assisting the decision-making of disease treatment. 2,3 In terms of structure, prefoldin has a special and flexible hydrophobic protein binding region, which can capture proteins. Therefore, it can be used as a nanobiological template and designed as a nanoactuator to capture nanocargoes with different charges and various sizes.…”